Anupam Rasayan India share price & results

Anupam Rasayan India Limited· Chemicals· Commodities

Results to: Sept 2026
Latest analysed call: Q1 FY27
Ownership as of: Sept 2026

Custom-synthesis specialty chemicals & CDMO maker for agrochem, pharma, personal care clients.

Company research is public. Sign in to keep your own companies, notes and cases.

Inve AI Signals on ANURAS

Direct bridge to live research & tools watching Anupam Rasayan India Limited

Guidance Hit Rate

16 targets · 50% hit rate 2 achieved · 12 active →

Segment Shift

Sector & Mix Compare sector growth & peers →

Reverse DCF

Implied Growth Test priced-in growth in DCF tool →

Concall & Tone

Q1 FY27 analysed Read claims, qualifiers & Q&A →

Price & Snapshot

₹1,198.3 +1.05% · +₹12.5

Last close 9 Nov 2026 · NSE · INR · Source: Inve

Performance +10.7% 1Y

1Y: ₹1,082.9 on 7 Nov 2025 → ₹1,198.3. High ₹1,376 (15 May 2026), low ₹1,071.8 (12 Nov 2025).

Previous close: ₹1,185.8
Market cap: ₹13.6k Cr
52-week range: ₹1,071.8 – ₹1,376
One year: +10.83%
Price to earnings (TTM to Sept 2026): 75.79×
Return on equity (TTM to Sept 2026): 3.57%

Reported

Key financial metrics & valuation ratios

Each figure keeps its basis and period; nothing is filled in.

Metric	Value	Change	Basis	Period	Note
Revenue	397 ₹ crore	−32.5% YoY	Quarterly, as filed	Quarter to Sept 2026	Revenue from operations as filed.
Operating margin	32.0 %	+13.0 pts YoY	Operating profit / revenue	Quarter to Sept 2026	For the quarter; a change is in percentage points.
Net profit	46.0 ₹ crore	+12.2% YoY	Quarterly, as filed	Quarter to Sept 2026	Profit after tax as filed.
Return on equity	3.57 %	+2.2 ptsFY Mar 2026 vs FY Mar 2025	Trailing twelve months	TTM to Sept 2026	Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin	-9.30 %	+21.3 ptsFY Mar 2026 vs FY Mar 2025	Fiscal year	FY ending Mar 2026	(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)	23.83 %	+67.2 ptsFY Mar 2026 vs FY Mar 2025	Trailing twelve months	TTM to Sept 2026	Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Sept 2026

Guidance

What management said, and what became of it

2 of 4 judged targets kept · 12 open · verdicts reflect calls analysed to Q1 FY27.

Target	Original wording	Said	Latest call	Verdict
Operations Jayhawk Acquisition EPS Impact	EPS-accretive from day one Call transcript, Q2 FY26 · 17 Oct 2025	Q2 FY26	Q1 FY27:Promise of 'EPS-accretive from day one' remains unaddressed. Management noted PAT growth lagged EBITDA due to higher depreciation from Jayhawk, but did not clarify the net EPS impact. Call transcript, Q1 FY27 · 14 Aug 2026	Ghosted
Operations Sustainable EBITDA Margin	26% to 28% EBITDA margin Call transcript, Q3 FY25 · 19 Feb 2025	Q3 FY25	Q1 FY27:Reported 26% consolidated EBITDA margin, within the original target range. However, new long-term guidance is for 22-24% consolidated, below the original 26-28% target. Call transcript, Q1 FY27 · 14 Aug 2026	Missed
Growth FY26 Revenue Growth	30% to 35% revenue increase in FY '26 Call transcript, Q3 FY25 · 19 Feb 2025	Q3 FY25	Q4 FY26:Achieved 65% YoY growth for FY26, exceeding the revised target of >50%. Call transcript, Q4 FY26 · 25 May 2026	Achieved

Source: Inve Guidance Tracker for Anupam Rasayan India Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

2 of Anupam Rasayan India Limited's 16 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 13 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.

See the full record

Supply chain

Cross-company call evidence

Named counterparties and similar headwinds disclosed on earnings calls.

Relationship Period Lifecycle

Counterparties named by Anupam Rasayan India Limited

Anupam Rasayan India Limited → acquires or invests in → Bliss GVS Pharma Limited (BLISSGVS).

Q1 FY27 · Announced · Positive · Linked listed company
1. Proposed
2. Announced
3. Active
4. Completed / ended
Transformational step for building a more complete pharmaceutical platform, moving into formulations, regulated manufacturing, and global market access. Provides headroom for capacity utilization and a robust pipeline of 62 molecules.

“At the same time, the proposed acquisition of Bliss GVS Pharma continues to progress as planned following the signing of the definitive agreements.”

Disclosure indicates an acquisition or investment without specifying full buyout versus minority stake.

Evidence drawer

Evidence type: Transcript excerpt

“At the same time, the proposed acquisition of Bliss GVS Pharma continues to progress as planned following the signing of the definitive agreements.”

Source company: Anupam Rasayan India Limited · Counterparty: Bliss GVS Pharma Limited (BLISSGVS) · Call date: 2026-08-14 · Period: Q1 FY27 · Review status: Structured call extraction
Anupam Rasayan India Limited → acquires or invests in → Bliss GVS Pharma Limited (BLISSGVS).

Q4 FY26 · Announced · Positive · Linked listed company
1. Proposed
2. Announced
3. Active
4. Completed / ended
Build an integrated global life science and specialty pharmaceutical platform, strengthen presence across pharmaceutical value chain from key starting materials to finished dosage formulations, established capabilities in niche dosage forms across therapeutic segments, strong international footprint.

“we have entered into a definitive agreement to acquire 43.3% to 48.2% equity stake along with an open offer of up to 26% additional shares to public shareholders of Bliss GVS Pharma Limited. This marks another important milestone in Anupam Rasayan's vision of building an integrated global life science and specialty pharmaceutical platform.”

Disclosure indicates an acquisition or investment without specifying full buyout versus minority stake.

Evidence drawer

Evidence type: Transcript excerpt

“we have entered into a definitive agreement to acquire 43.3% to 48.2% equity stake along with an open offer of up to 26% additional shares to public shareholders of Bliss GVS Pharma Limited. This marks another important milestone in Anupam Rasayan's vision of building an integrated global life science and specialty pharmaceutical platform.”

Source company: Anupam Rasayan India Limited · Counterparty: Bliss GVS Pharma Limited (BLISSGVS) · Call date: 2026-05-25 · Period: Q4 FY26 · Review status: Structured call extraction
Anupam Rasayan India Limited → acquires or invests in → Jayhawk Fine Chemicals.

Q1 FY27 · Closed / completed · Positive · Counterparty named; listed-company identity not verified.
1. Proposed
2. Announced
3. Active
4. Completed / ended
Strengthens global platform, US manufacturing, advanced/high-purity chemistries, access to high-value markets (semiconductors, automotive, EV, aviation, performance materials).

“On the strategic front, our Jayhawk acquisition is already strengthening our global platform. It gives us a strategic manufacturing base in the U.S., expands our capabilities in advanced and high-purity chemistries and provides a strong platform to participate in high-value markets such as semiconductors, automotive, EV, aviation and performance materials.”

Disclosure indicates an acquisition or investment without specifying full buyout versus minority stake.

Evidence drawer

Evidence type: Transcript excerpt

“On the strategic front, our Jayhawk acquisition is already strengthening our global platform. It gives us a strategic manufacturing base in the U.S., expands our capabilities in advanced and high-purity chemistries and provides a strong platform to participate in high-value markets such as semiconductors, automotive, EV, aviation and performance materials.”

Source company: Anupam Rasayan India Limited · Counterparty: Jayhawk Fine Chemicals · Call date: 2026-08-14 · Period: Q1 FY27 · Review status: Structured call extraction
Anupam Rasayan India Limited → acquires or invests in → Jayhawk Fine Chemicals.

Q4 FY26 · Closed / completed · Positive · Counterparty named; listed-company identity not verified.
1. Proposed
2. Announced
3. Active
4. Completed / ended
Strategic manufacturing footprint in the U.S., strengthens advanced custom synthesis capabilities, expands access to innovation-led and highly regulated markets, deepens relationships with multinational customers, increases participation in high-growth sectors like defense and semiconductors.

“we have successfully completed the acquisition of Jayhawk Fine Chemicals. And this acquisition provides us with a strategic manufacturing footprint in the U.S., strengthens our advanced custom synthesis capabilities and expands our access to innovation-led and highly regulated markets.”

Disclosure indicates an acquisition or investment without specifying full buyout versus minority stake.

Evidence drawer

Evidence type: Transcript excerpt

“we have successfully completed the acquisition of Jayhawk Fine Chemicals. And this acquisition provides us with a strategic manufacturing footprint in the U.S., strengthens our advanced custom synthesis capabilities and expands our access to innovation-led and highly regulated markets.”

Source company: Anupam Rasayan India Limited · Counterparty: Jayhawk Fine Chemicals · Call date: 2026-05-25 · Period: Q4 FY26 · Review status: Structured call extraction
Anupam Rasayan India Limited → acquires or invests in → Jayhawk Fine Chemicals.

Q3 FY26 · Announced · Positive · Counterparty named; listed-company identity not verified.
1. Proposed
2. Announced
3. Active
4. Completed / ended
Expand geographical footprint in US, enhance access to fast-growing innovation-led end markets (semiconductors, automotive, EV, Pharma, aviation, electronics), strengthen platform depth, and secure uninterrupted access to key raw materials for fluorination chemistry.

“In a similar spirit of expanding our geographical footprint and access to high value and critical end markets, during the quarter, we have signed a definitive agreement to acquire 100% equity in Jayhawk Fine Chemicals, a US-based specialty chemicals company from the CABB Group. ... This acquisition is aligned with our long-term objective of evolving into global specialty chemical platform serving key geographies, high growth and high value sectors. ... we expect the acquisition to be EPS accretive from day one.”

Disclosure indicates an acquisition or investment without specifying full buyout versus minority stake.

Evidence drawer

Evidence type: Transcript excerpt

“In a similar spirit of expanding our geographical footprint and access to high value and critical end markets, during the quarter, we have signed a definitive agreement to acquire 100% equity in Jayhawk Fine Chemicals, a US-based specialty chemicals company from the CABB Group. ... This acquisition is aligned with our long-term objective of evolving into global specialty chemical platform serving key geographies, high growth and high value sectors. ... we expect the acquisition to be EPS accretive from day one.”

Source company: Anupam Rasayan India Limited · Counterparty: Jayhawk Fine Chemicals · Call date: 2026-02-14 · Period: Q3 FY26 · Review status: Structured call extraction
Anupam Rasayan India Limited → acquires or invests in → Jayhawk Fine Chemicals.

Q2 FY26 · Announced · Positive · Counterparty named; listed-company identity not verified.
1. Proposed
2. Announced
3. Active
4. Completed / ended
Strengthen global presence, direct US manufacturing, expand performance material portfolio, access fast-growing end markets, enhance chemistry/capability/customer platform, leverage geopolitical tailwinds.

Disclosed value: USD 150 million

“On 9 December 2025, we signed a definitive agreement to acquire 100% equity in Jayhawk Fine Chemicals, a US-based specialty chemicals company from the CABB Group. Jayhawk reported approximately USD78 million revenue in CY24 with EBITDA margins of around 19%. Total purchase consideration is approximately 150 million, including cash on Jayhawk's balance sheet, which is roughly around 16 million. The funding structure involves Anupam Rasayan investing 40 million through a combination of internal accruals and debt, and the balance, which is roughly 110 million, is being invested by a leading global investment management firm in the form of Class B non-voting shares, which will enable Anupam Rasayan to consolidate Jayhawk fully. we expect the acquisition to be EPS-accretive from day one.”

Disclosure indicates an acquisition or investment without specifying full buyout versus minority stake.

Evidence drawer

Evidence type: Transcript excerpt

“On 9 December 2025, we signed a definitive agreement to acquire 100% equity in Jayhawk Fine Chemicals, a US-based specialty chemicals company from the CABB Group. Jayhawk reported approximately USD78 million revenue in CY24 with EBITDA margins of around 19%. Total purchase consideration is approximately 150 million, including cash on Jayhawk's balance sheet, which is roughly around 16 million. The funding structure involves Anupam Rasayan investing 40 million through a combination of internal accruals and debt, and the balance, which is roughly 110 million, is being invested by a leading global investment management firm in the form of Class B non-voting shares, which will enable Anupam Rasayan to consolidate Jayhawk fully. we expect the acquisition to be EPS-accretive from day one.”

Source company: Anupam Rasayan India Limited · Counterparty: Jayhawk Fine Chemicals · Call date: 2025-12-15 · Period: Q2 FY26 · Review status: Structured call extraction

Mentions over time

First observed: Q3 2025 · Latest observed: Q2 2026

Recorded disclosures by calendar reporting quarter
Period	Other calls	Own calls
Q2 2026	0	2
Q1 2026	0	2
Q4 2025	0	1
Q3 2025	0	1

Counts reflect the calls covered here. No mention in a period does not establish that a relationship ended.

From available earnings-call summaries. Disclosures are management statements, not independently verified transactions.

Live Summary

ANURAS ₹1,198.3 +1.05%

Guidance Verdict (16 tracked) 2 kept · 12 open· 2 missed

AI Call Brief · Q1 FY27

Anupam Rasayan India Limited Q1 FY27

Overview

Symbol: NSE:ANURAS
Sector: Chemicals
Industry: Commodities
Exchange: NSE
Currency: INR

What Anupam Rasayan India Limited does

Based on the company's own presentations, annual report and earnings calls.

Anupam Rasayan India is a custom-synthesis specialty chemicals and CDMO manufacturer that develops and produces complex intermediates and active ingredients for agrochemical, pharmaceutical, personal-care and performance-materials customers worldwide. It operates a backward-integrated fluorination platform through its majority-owned subsidiary Tanfac Industries, a hydrofluoric-acid and fluorine-derivatives producer, and expanded into the U.S. specialty-chemicals and CDMO market through the acquisition of Jayhawk Fine Chemicals Corporation in Kansas. The company earns revenue through long-term supply relationships with multinational agrochemical, pharma and electronics clients, built on deep process expertise in complex chemistries such as fluorination, chlorination, bromination, etherification and photo/flow chemistry. It has also signed a definitive agreement to acquire a controlling stake in Bliss GVS Pharma to extend further into the pharmaceutical value chain.

Segments

Life Science Related Specialty Chemicals
Performance Materials

Manufacturing plants: 8 plants (4 in Sachin, 2 in Jhagadia - Gujarat; 1 in Cuddalore, Tamil Nadu via Tanfac; 1 in Kansas, USA via Jayhawk)
Total installed manufacturing capacity: ~2,00,552 MT per annum across all plants
R&D centres: 4 (Sachin, Jhagadia, Tanfac, Jayhawk)
R&D team: 90+ professionals, including 10% PhDs and 75+ chemical engineers
Sales offices: 5 (India, Japan, Switzerland, USA, UAE)
Export presence: 14+ countries

Founded 1984Headquarters Surat, Gujarat, India Company website

How the price took the results

Moved an average of ±2.3% across the last 3 priced result releases

Close before → close after

Quarter	Release	Revenue (₹ Cr)	Net profit (₹ Cr)	Rev YoY	Before → After	Reaction
Q1 FY27	14 Aug 26	329	32	+4.1%	₹1,207.8 → ₹1,209.4	+0.1%
Q4 FY26	25 May 26	371	42	+12.1%	₹1,366.1 → ₹1,371.1	+0.4%
Q3 FY26	14 Feb 26	401	48	+89.2%	₹1,336.4 → ₹1,249.7	−6.5%

The move from the last close before each results date to the first close on or after it — the market's first read on the quarter alongside what was filed.

Guidance

What management said, and what became of it

2 of 4 judged targets kept · 12 open · verdicts reflect calls analysed to Q1 FY27.

Target	Original wording	Said	Latest call	Verdict
Operations Jayhawk Acquisition EPS Impact	EPS-accretive from day one Call transcript, Q2 FY26 · 17 Oct 2025	Q2 FY26	Q1 FY27:Promise of 'EPS-accretive from day one' remains unaddressed. Management noted PAT growth lagged EBITDA due to higher depreciation from Jayhawk, but did not clarify the net EPS impact. Call transcript, Q1 FY27 · 14 Aug 2026	Ghosted
Operations Sustainable EBITDA Margin	26% to 28% EBITDA margin Call transcript, Q3 FY25 · 19 Feb 2025	Q3 FY25	Q1 FY27:Reported 26% consolidated EBITDA margin, within the original target range. However, new long-term guidance is for 22-24% consolidated, below the original 26-28% target. Call transcript, Q1 FY27 · 14 Aug 2026	Missed
Growth FY26 Revenue Growth	30% to 35% revenue increase in FY '26 Call transcript, Q3 FY25 · 19 Feb 2025	Q3 FY25	Q4 FY26:Achieved 65% YoY growth for FY26, exceeding the revised target of >50%. Call transcript, Q4 FY26 · 25 May 2026	Achieved

Source: Inve Guidance Tracker for Anupam Rasayan India Limited · to Q1 FY27

The full ledger

Open Anupam Rasayan India Limited’s full ledger

A free account opens 5 company ledgers a month. All 16 tracked commitments, with each call’s wording and source.

Browse the register

Latest analysed call: Q1 FY27, 14 Aug 2026. 6 calls analysed.

No analysed call after Q1 FY27, though results run to Sept 2026.

Call summaries

Q1 FY27 — 14 Aug 2026

Anupam Rasayan India Limited Q1 FY27

Anupam Rasayan India Limited reported a strong start to FY27 with consolidated total income growing 36% year-on-year, driven by new product commercialization and robust demand. The company achieved a global first by commercializing ETFA using flow chemistry and saw significant contributions from the Jayhawk acquisition. While EBITDA margins remained healthy, PAT growth was tempered by higher depreciation. The acquisition of Bliss GVS Pharma is on track, further strengthening the company's integrated pharmaceutical platform.

Read the full call

Q4 FY26 — 25 May 2026

Anupam Rasayan Q4 FY26

Anupam Rasayan reported a landmark FY26 with its highest ever revenue of INR2,384 crores, a 65% YoY increase, and a significant rise in PAT to INR222 crores. The company strategically expanded its portfolio through the acquisition of Jayhawk Fine Chemicals and a definitive agreement to acquire a controlling stake in Bliss GVS Pharma, aiming to build an integrated global life science and specialty pharmaceutical platform. While Q4 FY26 saw a slight dip in EBITDA and PAT compared to Q4 FY25, management expressed confidence in future growth driven by diversified revenue streams and synergistic ac

Read the full call

Q3 FY26 — 14 Feb 2026

Anupam Rasayan Q3 FY26

Anupam Rasayan reported strong financial performance for Q3 and 9MFY26, driven by commercial molecule scale-up and improved capacity utilization. The company announced the strategic acquisition of Jayhawk Fine Chemicals, aiming to expand its global footprint and access high-value end markets. Segmental growth was robust, particularly in Pharma and Performance Material, contributing to a diversified revenue mix.

Read the full call

Summaries of each call, in Inve’s own words; the transcript is not reproduced. Not investment advice.

Every analysed call

Anupam Rasayan India Limited earnings calls (ANURAS)

Fundamentals

Valuation, return & balance-sheet ratios

Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).

Trailing twelve months
4.70% TTM to Sept 2026
Fiscal year
7.38% FY ending Mar 2026

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
9.93% 11.11% 12.59% 8.88% 7.33% 7.38%

How it is calculated. Adjusted EBIT ÷ average capital employed, including minority equity and deposits.
Trailing twelve months
3.57% TTM to Sept 2026
Fiscal year
5.55% FY ending Mar 2026

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
6.55% 9.21% 8.83% 4.87% 3.31% 5.55%

How it is calculated. Adjusted profit attributable to owners ÷ average owners’ equity.
Trailing twelve months
2.04% TTM to Sept 2026
Fiscal year
3.36% FY ending Mar 2026

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
3.53% 5.86% 6.51% 3.89% 3.24% 3.36%

How it is calculated. Total profit excluding exceptional items after tax ÷ average total assets.
Trailing twelve months
23.50% TTM to Sept 2026
Fiscal year
22.24% FY ending Mar 2026

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
23.92% 28.40% 26.90% 25.83% 27.91% 22.24%

How it is calculated. Operating profit ÷ revenue.
Trailing twelve months
8.93% TTM to Sept 2026
Fiscal year
9.43% FY ending Mar 2026

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
8.63% 14.15% 13.55% 11.05% 11.13% 9.43%

How it is calculated. Total profit excluding exceptional items after tax ÷ revenue.
Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
-17.88% -29.61% 14.42% -43.66% -30.62% -9.30%

How it is calculated. (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
1.43% -112.50% 134.56% 35.33% -18.75% 150.45%

How it is calculated. Operating cash flow ÷ reported total net profit.
Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
18.00% 13.69% 13.80% 48.54% 28.53% 23.47%

How it is calculated. Fixed-asset purchases ÷ revenue.
Trailing twelve months
23.83% TTM to Sept 2026
Fiscal year
64.58% FY ending Mar 2026

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
53.31% 32.43% 49.16% -7.93% -2.58% 64.58%

How it is calculated. Revenue change against the same period one year earlier.
Trailing twelve months
19.21% TTM to Sept 2026
Fiscal year
83.62% FY ending Mar 2026

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
32.08% 117.14% 19.08% -30.98% -25.56% 83.62%

How it is calculated. Adjusted profit attributable to owners vs the same period one year earlier.
Trailing twelve months
16.10% TTM to Sept 2026
Fiscal year
31.17% FY ending Mar 2026

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
43.70% 57.22% 41.31% -11.60% 5.25% 31.17%

How it is calculated. Operating profit vs the same period one year earlier.
Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
0.27× 0.48× 0.35× 0.39× 0.48× 0.57×

How it is calculated. Borrowings ÷ owners’ equity.
Trailing twelve months
2.51× TTM to Sept 2026
Fiscal year
2.71× FY ending Mar 2026

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
2.45× 8.17× 5.89× 3.66× 2.77× 2.71×

How it is calculated. Adjusted EBIT ÷ interest expense.
Trailing twelve months
0.23× TTM to Sept 2026
Fiscal year
0.36× FY ending Mar 2026

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
0.41× 0.41× 0.48× 0.35× 0.29× 0.36×

How it is calculated. Revenue ÷ average total assets.
Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
₹127.00 Cr ₹626.00 Cr ₹258.00 Cr ₹780.00 Cr ₹1,245.00 Cr ₹1,473.00 Cr

How it is calculated. Borrowings less cash equivalents.
Trailing twelve months
2.73× TTM to Sept 2026
Fiscal year
2.71× FY ending Mar 2026

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
0.57× 2.00× 0.58× 1.92× 3.02× 2.71×

How it is calculated. (Borrowings − cash equivalents) ÷ adjusted EBITDA.
Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
1.26× 1.50× 1.41× 1.52× 1.73× 2.01×

How it is calculated. Average total assets ÷ closing owners’ equity.
Trailing twelve months
75.79× TTM to Sept 2026
Fiscal year
79.89× FY ending Mar 2026

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
— — — — — —

How it is calculated. Current market cap ÷ adjusted profit attributable to owners for the selected income period. Uses current market cap, not the share price at the period end.
Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
— — — — — —

How it is calculated. Market cap ÷ owners’ equity from the balance sheet selected for the TTM inputs. Uses current market cap, not the share price at the period end.
Trailing twelve months
23.82× TTM to Sept 2026
Fiscal year
27.78× FY ending Mar 2026

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
— — — — — —

How it is calculated. (Market cap + borrowings + deposits − cash equivalents) ÷ adjusted EBITDA. Uses current market cap, not the share price at the period end.
Trailing twelve months
2.97% TTM to Sept 2026
Fiscal year
2.67% FY ending Mar 2026

Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
— — — — — —

How it is calculated. Adjusted EBIT ÷ enterprise value. Uses current market cap, not the share price at the period end.
Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
92.00 days 95.00 days 95.00 days 143.00 days 186.00 days 148.00 days

How it is calculated. Reported receivable days from the annual accounts.
Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
530.00 days 852.00 days 483.00 days 627.00 days 876.00 days 490.00 days

How it is calculated. Reported inventory days, using material cost / cost of goods sold.
Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
215.00 days 225.00 days 167.00 days 247.00 days 348.00 days 261.00 days

How it is calculated. Reported payable days, using material cost / cost of goods sold.
Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
408.00 days 722.00 days 410.00 days 524.00 days 715.00 days 377.00 days

How it is calculated. Reported debtor days plus inventory days less payable days.
Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
168.00 days 218.00 days 153.00 days 138.00 days 160.00 days 108.00 days

How it is calculated. Reported net working capital days from the annual accounts.
Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
7.00% 7.00% 15.00% 11.00% 9.00% 10.00%

How it is calculated. Reported dividend payout as a percentage of annual profit.
Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
— — — — — —

How it is calculated. Market capitalisation from the current stock record.

Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
9.93%	11.11%	12.59%	8.88%	7.33%	7.38%

Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
6.55%	9.21%	8.83%	4.87%	3.31%	5.55%

Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
3.53%	5.86%	6.51%	3.89%	3.24%	3.36%

Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
23.92%	28.40%	26.90%	25.83%	27.91%	22.24%

Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
8.63%	14.15%	13.55%	11.05%	11.13%	9.43%

Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
-17.88%	-29.61%	14.42%	-43.66%	-30.62%	-9.30%

Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
1.43%	-112.50%	134.56%	35.33%	-18.75%	150.45%

Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
18.00%	13.69%	13.80%	48.54%	28.53%	23.47%

Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
53.31%	32.43%	49.16%	-7.93%	-2.58%	64.58%

Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
32.08%	117.14%	19.08%	-30.98%	-25.56%	83.62%

Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
43.70%	57.22%	41.31%	-11.60%	5.25%	31.17%

Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
0.27×	0.48×	0.35×	0.39×	0.48×	0.57×

Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
2.45×	8.17×	5.89×	3.66×	2.77×	2.71×

Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
0.41×	0.41×	0.48×	0.35×	0.29×	0.36×

Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
₹127.00 Cr	₹626.00 Cr	₹258.00 Cr	₹780.00 Cr	₹1,245.00 Cr	₹1,473.00 Cr

Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
0.57×	2.00×	0.58×	1.92×	3.02×	2.71×

Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
1.26×	1.50×	1.41×	1.52×	1.73×	2.01×

Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
—	—	—	—	—	—

Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
—	—	—	—	—	—

Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
—	—	—	—	—	—

Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
—	—	—	—	—	—

Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
92.00 days	95.00 days	95.00 days	143.00 days	186.00 days	148.00 days

Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
530.00 days	852.00 days	483.00 days	627.00 days	876.00 days	490.00 days

Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
215.00 days	225.00 days	167.00 days	247.00 days	348.00 days	261.00 days

Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
408.00 days	722.00 days	410.00 days	524.00 days	715.00 days	377.00 days

Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
168.00 days	218.00 days	153.00 days	138.00 days	160.00 days	108.00 days

Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
7.00%	7.00%	15.00%	11.00%	9.00%	10.00%

Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
—	—	—	—	—	—

A dash means inputs are missing or too old, the ratio does not apply, or the value is outside the supported range. FY uses the reported fiscal period; TTM the latest twelve months; valuations use the current market cap with the chosen earnings period. Screen Indian stocks on these ratios →

Financials

Quarterly & annual financial statements

Net profit, year on year: +12% (quarter to sept 2026 against sept 2025).

Dec 2024	Mar 2025	Jun 2025	Sept 2025	Dec 2025	Mar 2026	Jun 2026	Sept 2026
212	331	316	588	401	371	329	397
140	225	221	479	301	270	219	272
72	106	94	109	101	101	109	126
34.0%	32.0%	30.0%	19.0%	25.0%	27.0%	33.0%	32.0%
-3	5	5	8	5	2	6	16
30	29	34	35	34	37	42	48
26	27	26	28	29	31	32	32
13	55	39	55	43	35	42	61
−47.0%	31.0%	24.0%	24.0%	−12.0%	−22.0%	23.0%	25.0%
19	38	30	41	48	42	32	46
1.74	3.46	2.70	3.64	4.21	3.72	2.81	4.01

Source: Inve data · income statement, quarterly · to Sept 2026

Sales 3Y CAGR +3.8%

Operating profit 3Y CAGR −0.6%

Net profit 3Y CAGR −6.2%

Mar 2023	Mar 2024	Mar 2025	Mar 2026
1,500	833	898	1,676
1,087	822	631	1,271
413	307	267	405
-3	26	12	20
62	88	106	140
69	71	92	114
278	175	81	172
195	117	72	161

Source: Inve data · income statement, annual · to Mar 2026

Mar 2022	Mar 2023	Mar 2024	Mar 2025	Sept 2025	Mar 2026
100	107	110	110	114	114
1,627	2,265	2,651	2,740	3,083	3,188
836	822	1,069	1,373	1,223	1,867
327	584	772	1,045	1,230	2,843
2,891	3,778	4,602	5,269	5,650	8,013
1,202	1,417	1,501	2,185	2,422	3,713
44	120	609	216	58	114
149	67	67	9	9	19
1,496	2,173	2,424	2,860	3,161	4,167
2,891	3,778	4,602	5,269	5,650	8,013

Source: Inve data · balance sheet · to Mar 2026

Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
1	-171	244	22	-65	274
-192	-412	-478	-362	-286	-656
416	384	376	398	192	356
224	-199	142	58	-160	-26
-144	-318	37	-602	-372	-169

Source: Inve data · cash flow · to Mar 2026

Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
92	95	106	176	266	200
528	849	626	849	1553	543
213	223	202	332	631	335
407	721	530	692	1188	408
168	222	177	162	218	125
10.0%	11.0%	11.0%	7.0%	5.0%	7.0%
7.0%	7.0%	16.0%	12.0%	11.0%	11.0%

Source: Inve data · annual ratios · to Mar 2026

Ownership

Who owns it — shareholding pattern

Promoters hold 59.07% as of Sept 2026; institutions added 2.81 pts since Jun 2026.

Promoters 0.00 pts 59.07%
Foreign institutions +0.93 pts 8.65%
Domestic institutions +1.88 pts 2.26%
Public −2.82 pts 30.00%

44,080 shareholders on the register.

Source: Exchange shareholding filings · to Sept 2026 · 8 filings held

Who was buying across the market this quarter

Who bought this quarter

since Jun 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

+0.61 pp 3.89% held
+0.12 pp 14.53% held

The same filing shows 2 holders trimming and 0 off the list — both are in the register beside this.

Who is on the register

Named in the Sep 2026 filing

Every holder of Anupam Rasayan India Limited above SEBI's 1% disclosure line, and what changed since Jun 2026.

Holder	Stake	Change
	31.80%	unchanged
	14.53%	+0.12 pp
	9.73%	unchanged
	6.84%	unchanged
	6.34%	unchanged
	3.89%	+0.61 pp
	3.64%	unchanged
FPI fund	2.31%	unchanged
FPI fund	1.49%	unchanged
FPI fund	1.48%	unchanged
	1.20%	−2.44 pp
	1.11%	−0.43 pp

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Mutual funds in ANURAS

Filings to Sep 2026

0 new, 0 added, 4 trimmed, 0 sold out — net −0.03 L shares (−3.6%).

Held by funds: ₹9 Cr; 5 schemes
Biggest holder: Nippon India Nifty Smallcap 250 Index Fund; ₹6 Cr · 0.2% of that fund

Scheme	Holding	Last month	Held since
Nippon India Nifty Smallcap 250 Index Fund Nippon India Mutual Fund	₹6 Cr	−0.02 L	Mar '26
SBI Nifty Smallcap 250 Index Fund SBI Mutual Fund	₹3 Cr	−0.01 L	Mar '26
Nippon India Nifty 500 Equal Weight Index Fund Nippon India Mutual Fund	₹1 Cr	−0.01 L	Mar '26
SBI Nifty 500 Index Fund SBI Mutual Fund	₹0 Cr	−0.00 L	Mar '26
SBI Nifty Small Cap 250 ETF SBI Mutual Fund	₹0 Cr	held	May '26

HDFC, Nippon India and SBI schemes, from their monthly disclosures. Changes are counted in shares, so a price move never looks like buying or selling.

Mutual funds Sep 2026

0 added, 4 trimmed — net −2,973 shares (−3.6%)

Funds are sitting on: -3%; vs est. average cost
Held by funds: ₹9 Cr; 5 schemes · ≈ 0.07% of the company
Biggest holder: Nippon India Nifty Smallcap 250 Index Fund; ₹6 Cr · 0.2% of that fund

Shares held by these funds +701%

Dec '22 79,462 shares Sep '26

Your own record

Start an Inve Case for Anupam Rasayan India Limited

Free account: one company. Everything above stays public.

Write why you follow Anupam Rasayan India Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Chemicals companies

PEER COMPARISON

Median ₹13,643 Cr Mkt Cap

All Chemicals companies → · Chemicals earnings growth →

Quick Answers

Frequently asked questions on Anupam Rasayan India Limited

Compiled directly from ANURAS's filed financial statements, earnings call transcripts, and ownership disclosures.

How did Anupam Rasayan India Limited (ANURAS) perform in its latest reported quarter (Sept 2026)?

For the quarter ended Sept 2026, Anupam Rasayan India Limited reported revenue of ₹397 Cr, net profit of ₹46 Cr, an operating margin of 32.0%. Diluted earnings per share stood at ₹4.01.

How is Anupam Rasayan India Limited (ANURAS) valued today, and what growth does the stock price imply?

Anupam Rasayan India Limited (ANURAS) trades at ₹1,198.3, with a market capitalization of ₹13.6k Cr.

Who owns Anupam Rasayan India Limited (ANURAS) — promoters, FIIs, DIIs, and mutual funds?

As of Sept 2026, Promoters hold 59.1%, FIIs hold 8.7%, DIIs hold 2.3%, Public shareholders hold 30.0%.

Learn to analyse Anupam Rasayan India Limited

Guides on how to read this kind of business and the numbers that matter.